Aktieanalys

Amniotics Q3 2022: Our Comments - Redeye

{newsItem.title}

Redeye Publicerad: 10 Nov 2022 11:45

Redeye comments on the events of the third quarter, including progress with the main candidate PulmoStem and the selection of a new CEO. We also discuss the company's financials and financing.

Länk till analysen i sin helhet: https://www.redeye.se/research/862405/amniotics-q3-2022-our-comments?utm_source=finwire&utm_medium=RSS

Nyheter om Amniotics

Läses av andra just nu

Om aktien Amniotics

Senaste nytt